SCHEMBL3560001

SCHEMBL3560001

CCOC(=O)c1cc(=O)n2nc(-c3ccccc3)cc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.55
HSD17B10 Q99714 2/20 0.55
RAB9A P51151 5/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
POLB P06746 1/20 0.50
KDM4E B2RXH2 3/20 0.49
HPGD P15428 3/20 0.49
TDP1 Q9NUW8 3/20 0.49
MEN1 O00255 2/20 0.49
GAA P10253 2/20 0.49
KMT2A Q03164 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
HPGDS O60760 1/20 0.49
RXFP1 Q9HBX9 2/20 0.47
TP53 P04637 1/20 0.47
ALDH1A1 P00352 4/20 0.47
NPC1 O15118 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13534960 0.79 PARP1 (0.51) MAPTHSD17B10RAB9AKDM4EHPGD
SCHEMBL4710332 0.78 ADORA3 (0.52) MAPTHSD17B10SMN1; SMN2POLBKDM4E
SCHEMBL1695429 0.77 RAB9A (0.50) MAPTHSD17B10RAB9ASMN1; SMN2KDM4E
SCHEMBL15191719 0.76 PARP1 (0.57) MAPTHSD17B10RAB9ASMN1; SMN2KDM4E
SCHEMBL20818971 0.75 RAB9A (0.44) MAPTHSD17B10RAB9ASMN1; SMN2POLB
SCHEMBL1613376 0.72 PLAT (0.49) MAPTHSD17B10RAB9ASMN1; SMN2POLB
SCHEMBL31468434 0.72 MEN1 (0.49) MAPTHSD17B10RAB9ASMN1; SMN2KDM4E
SCHEMBL31468348 0.72 PARP1 (0.58) MAPTHSD17B10RAB9ASMN1; SMN2KDM4E
SCHEMBL595997 0.71 ALPL (0.75) MAPTRAB9APOLBGAAKMT2A
SCHEMBL13501425 0.71 HSD17B10 (0.60) MAPTHSD17B10RAB9ASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662826-B2 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same SHIONOGI & CO., LTD. (JP) 2010-02-16 US disclosed
US-7662826-B2 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same SHIONOGI & CO., LTD. (JP) 2010-02-16 US disclosed
US-20060089362-A1 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same SHIONOGI & CO., LTD (JP) 2006-04-27 US disclosed
EP-1505068-A1 PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME SHIONOGI & CO., LTD. (JP) 2005-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089362-A1 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same NADK, PNPO, NQO1 MAPT 2839/4885HSD17B10 873/4885RAB9A 1511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.